Company Active PLC

Company profile

GSK PLC

UK company 03888792, incorporated on 6 December 1999.

Home | GSK

At GSK, we unite science, technology and talent to get ahead of disease together

Company number
03888792
Incorporated
6 Dec 1999
Companies House status
Active

Company identity

Founded / incorporated
6 December 1999

Company number 03888792

Verify at Companies House
Legal name
GSK PLC
Company type
Public Limited Company
Region
London
Registered address
79 NEW OXFORD STREET
LONDON
UNITED KINGDOM
WC1A 1DG
Insolvency history
No

Corporate ownership

Updated 07 Jul 2026 09:49

GSK PLC
No active corporate controller recorded.

Company events

Reference milestones and recent Companies House filing stream events.

14 events
13 Aug
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

30 Jun
2027

Accounts due

Accounts Due

Next accounts due date

07 Aug
2026

Capital Allotment Shares

Capital

SH01 | Transaction MzUzNzUzOTg1NmFkaXF6a2N4

Published 07 Aug 2026 11:23

31 Jul
2026

Confirmation Statement With No Updates

Confirmation-statement

CS01 | Transaction MzUzNjA1MjYwOGFkaXF6a2N4

Published 31 Jul 2026 08:45

30 Jul
2026

Confirmation statement filed

Confirmation

Last confirmation statement made up date

09 Jul
2026

Capital Allotment Shares

Capital

SH01 | Transaction MzUzMTQ3OTU3MWFkaXF6a2N4

Published 09 Jul 2026 12:05

02 Jul
2026

Capital Return Purchase Own Shares Treasury Capital Date

Capital

SH03 | Transaction MzUyNzQ5NTc0NWFkaXF6a2N4 | Paper/PDF filed

Published 03 Jul 2026 00:47

22 Jun
2026

Capital Allotment Shares

Capital

SH01 | Transaction MzUyNzc4OTQzN2FkaXF6a2N4

Published 22 Jun 2026 14:27

05 Jun
2026

Capital Return Purchase Own Shares Treasury Capital Date

Capital

SH03 | Transaction MzUyMzcxNjQzMWFkaXF6a2N4 | Paper/PDF filed

Published 09 Jun 2026 23:08

24 May
2026

Memorandum Articles

Incorporation

MA | Transaction MzUyMTUyMTI1NGFkaXF6a2N4 | Paper/PDF filed

Published 25 May 2026 22:31

24 May
2026

Resolution

Resolution

RESOLUTIONS | Transaction QUYxVUE1MTZhZGlxemtjeA | Paper/PDF filed

Published 25 May 2026 22:31

24 May
2026

Resolution

Resolution

RESOLUTIONS | Transaction WUYxSzlTMkFhZGlxemtjeA | Paper/PDF filed

Published 25 May 2026 22:31

31 Dec
2025

Accounts filed

Accounts

Last accounts made up date

06 Dec
1999

Incorporated

Inception

Company registered at Companies House

Public funding

29 awards
First funded
2005
Funded years
2005, 2006, 2009, 2010, 2011, 2012, 2013, 2018, 2019, 2020, 2023, 2024
Age at first award
5 years

Projects

2024 Knowledge Transfer Partnership

London School of Hygiene and Tropical Medicine and GSK Plc KTP 23_24 R5

1 Nov 2024 to 31 Oct 2027

Awarded
£0
Total cost £0

To employ recent statistical innovations and introduce 'trial emulation' into the drug development process within pharmaceutical industry leader GSK to help design future research and accelerate access to drugs. Emulated trials use available data enabling faster exploration of hypotheses for new treatments without the need for a new clinical trial.

2023 Knowledge Transfer Partnership

University of Strathclyde and GlaxoSmithKline Plc KTP22_23 R1

6 Apr 2023 to 6 Apr 2025

Awarded
£0
Total cost £0

The project will deliver significant improvements in speed and quality of pharmaceutical product manufacturing processes. This will be achieved through an embedded understanding of the impact of pressure on polymorphs in active pharmaceutical ingredients (APIs), which impacts product stability and biopharmaceutics, ultimately resulting in increased profit...

2020 Study

Identification of new Parkinson's genes playing a role in mitochondrial quality control

1 Dec 2020 to 30 Nov 2023

Awarded
£0
Total cost £0

Currently, there are no disease-modifying treatments that can prevent or slow down PD. PD, like other neurodegenerative conditions, is a disorder involving both genetic (e.g. _PINK1_ and _Parkin_ genes) and environmental factors (e.g. age, pesticides). Recently, multiple regions of PD patient's DNA were found to be different to those not having the diseas...

2020 Study

Use of AI/ML and Digital Health tools in tuberculosis drug development - a feasibility study

1 Dec 2020 to 30 Nov 2023

Awarded
£0
Total cost £0

The project herein involves evaluating whether AI and other digital tools can improve understanding of how to progress tuberculosis science to mitigate its global burden. Tuberculosis is the leading global infectious threat and the poor are disproportionately affected. With the increasing burden of HIV-tuberculosis co-infections, tuberculosis has become a...

2020 Collaborative R&D

Next-generation Digital Design technology for Formulated Products involving complex materials

1 Jul 2020 to 30 Jun 2022

Awarded
£0
Total cost £199,784

New therapeutic products in the pharma industries are invariably large, complex chemical molecules -- e.g., synthetic active ingredients, amino acids, peptides etc. In the consumer goods and food industries, complex emulsions form the backbone of products such as detergents, beauty products, milk and other liquid-based foods. An essential pre-requisite fo...

2020 Collaborative R&D

Smart Connected Shop Floor

1 May 2020 to 31 Oct 2022

Awarded
£503,055
Total cost £1,289,885

Public description Industrial Digital Technologies (IDT's) are disrupting industries across the globe. The breadth and depth of these changes herald the transformation of entire systems of production, management, and governance. There is overwhelming evidence that IDTs can provide a step change in industrial productivity(2). The Smart Connected Factory is...

2020 Collaborative R&D

Digital Design Accelerator Platform to Connect Active Material Design to Product Performance

1 Mar 2020 to 31 Aug 2022

Awarded
£0
Total cost £899,999

.

2019 Knowledge Transfer Partnership

Birmingham City University and GlaxoSmithKline plc

1 Oct 2019 to 30 Sep 2021

Awarded
Unknown

To transform both the depth and quality of consumer driven insights into brand perception, captured by the Shopper Science Laboratory, using a suite of novel interactive Augmented Reality technologies, leading to new product creation and a wider market share.

2019 Collaborative R&D Lead participant

Genomic Main Phase - Early Diagnosis

1 Aug 2019 to 31 Mar 2020

Awarded
£12,500,000
Total cost £12,500,000

Awaiting Public Project Summary

2019 Collaborative R&D

London Medical Imaging & Artificial Intelligence Centre for Value-Based Healthcare

1 Feb 2019 to 31 Mar 2023

Awarded
£0
Total cost £447,893

"The London Medical Imaging & Artificial Intelligence Centre for Value-Based Healthcare will improve NHS patient care and health outcomes, reduce healthcare costs and support the growth of companies, supporting the economy. It will do this by applying artificial intelligence technologies to medical imaging (for example MRI scans, CT scans PET scans and ul...

2018 Collaborative R&D Lead participant

Methyl Transferases for the Functional Diversification of Bioactives

1 Apr 2018 to 30 Sep 2021

Awarded
£191,920
Total cost £383,840

Awaiting Public Project Summary

2018 Collaborative R&D

Terahertz real-time release testing for pharmaceutical products

1 Feb 2018 to 31 Jan 2020

Awarded
£20,206
Total cost £40,411

The project will develop a new, rapid and non-destructive test instrument for predicting tablet efficacy and performance, based on direct measurements of tablet porosity using terahertz light. In so doing, we expect to contribute to manufacturing efficiency improvements in production of advanced solid dose medicines. Our technology will initially be marke...

Product types

Collaborative R&D Feasibility Studies Knowledge Transfer Partnership Study